Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Conclusions: Our interim taxonomic analyses of 26 patients suggest that the taxonomic identity of the microbiomes were largely similar across indications and timepoints, but the relative abundances of the phylotypes differed between samples. While our results suggest that Bacteroidetes and Verrucomicrobia at conditioning and engraftment may correlate with the likelihood of Short-PFS versus Long-PFS, our results need to be validated in ongoing cohort expansion studies.DisclosuresBiran: Celgene: Consultancy, Honoraria, Speakers Bureau; Merck: Research Funding; Takeda: Consultancy, Speakers Bureau; BMS: Research Funding; Amgen: Consultancy, Speakers Bureau. Siegel: Takeda: Consultancy, Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Amgen: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Merck: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; Karyopharm: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau. Vesole: Amgen: Speakers Bureau; Takeda: Speakers Bureau. Munshi: Kite: Speakers Bureau. Atkins: BMS: Consultancy; Merck: Consultancy. Feldman: Johnson and Johnson: Speakers Bureau; Portola: Research Funding; Celgene: Speakers Bureau; KITE: Speakers Bureau; Janssen: Speakers Bureau; Seattle Genetics: Research Funding, Speakers Bureau; Pharmacyclics: Speakers Bureau. Skarbnik: Genentech: Honoraria, Speakers Bureau; Gilead Sciences: Honoraria, S...
Source: Blood - Category: Hematology Authors: Tags: 731. Clinical Autologous Transplantation: Results: Poster II Source Type: research